Comparison of Magnetic Resonance Imaging Mismatch Criteria to Select Patients for Endovascular Stroke Therapy Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 Investigators

perfusion–diffusion (perfusion-weighted imaging–diffusion-weighted imaging, PWI–DWI) mismatch: patients with mismatch have a favorable clinical response to reperfusion, whereas patients without mismatch do not. This study examined whether alternative mismatch criteria can also differentiate patients according to their response to reperfusion. Methods —Patients from the DEFUSE 2 study were categorized according to vessel occlusion on magnetic resonance angiography (MRA) and DWI lesion volume criteria (MRA–DWI mismatch) and symptom severity and DWI criteria (clinical–DWI mismatch). Favorable clinical response was defined as an improvement of ≥ 8 points on the National Institutes of Health Stroke Scale (NIHSS) by day 30 or an NIHSS score of ≤ 1 at day 30. We assessed, for each set of criteria, whether the association between reperfusion and favorable clinical response differed according to mismatch status. Results —A differential response to reperfusion was observed between patients with and without MRA–DWI mismatch defined as an internal carotid artery or M1 occlusion and a DWI lesion <50 mL. Reperfusion was associated with good functional outcome in patients who met these MRA–DWI mismatch criteria (odds ratio [OR], 8.5; 95% confidence interval [CI], 2.3–31.3), whereas no association was observed in patients who did not meet these criteria (OR, 0.5; 95% CI, 0.08–3.1; P for difference between the odds, 0.01). No differential response to reperfusion was observed with other variations of the MRA–DWI or clinical–DWI mismatch criteria. Conclusions —The MRA–DWI mismatch is a promising alternative to DEFUSE 2’s PWI–DWI mismatch for patient selection in endovascular stroke trials. ( Stroke . 2014;45:1369-1374.) analysis were retained in the model. We evaluated the difference in the response to reperfusion between patients with and without mismatch using regres- sion models that included the significant covariates and the interaction between reperfusion and mismatch status as independent variables: where C is a constant, R is the presence of reperfusion, and is the presence of mismatch. All analyses were conducted with and Stats Direct.

[1]  M. Siket,et al.  Treatment of Acute Ischemic Stroke. , 2016, Emergency medicine clinics of North America.

[2]  R. Bammer,et al.  Patients with Single Distal MCA Perfusion Lesions Have a High Rate of Good Outcome with or without Reperfusion , 2014, International journal of stroke : official journal of the International Stroke Society.

[3]  G. Zaharchuk,et al.  ( DEFUSE 2 ) Investigators for Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 , 2014 .

[4]  Max Wintermark,et al.  A trial of imaging selection and endovascular treatment for ischemic stroke. , 2013, The New England journal of medicine.

[5]  Manabu Inoue,et al.  MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study , 2012, The Lancet Neurology.

[6]  R. Gonzalez,et al.  Clinical MRI of acute ischemic stroke , 2012, Journal of magnetic resonance imaging : JMRI.

[7]  Geoffrey A. Donnan,et al.  RAPID Automated Patient Selection for Reperfusion Therapy: A Pooled Analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study , 2011, Stroke.

[8]  R. Bammer,et al.  Real‐time diffusion‐perfusion mismatch analysis in acute stroke , 2010, Journal of magnetic resonance imaging : JMRI.

[9]  AlexAbou-Chebl Endovascular Treatment of Acute Ischemic Stroke May Be Safely Performed With No Time Window Limit in Appropriately Selected Patients , 2010 .

[10]  A. Abou-Chebl,et al.  Endovascular Treatment of Acute Ischemic Stroke May Be Safely Performed With No Time Window Limit in Appropriately Selected Patients , 2010, Stroke.

[11]  Alan Connelly,et al.  The Physiological Significance of the Time-to-Maximum (Tmax) Parameter in Perfusion MRI , 2010, Stroke.

[12]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[13]  W. Hacke,et al.  Mismatch-Based Delayed Thrombolysis: A Meta-Analysis , 2010, Stroke.

[14]  R. Gonzalez,et al.  MRI-Based Selection for Intra-Arterial Stroke Therapy: Value of Pretreatment Diffusion-Weighted Imaging Lesion Volume in Selecting Patients With Acute Stroke Who Will Benefit From Early Recanalization , 2009, Stroke.

[15]  S. Warach,et al.  Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.

[16]  R. Hakimelahi,et al.  Neuroimaging of ischemic stroke with CT and MRI: advancing towards physiology-based diagnosis and therapy , 2009, Expert review of cardiovascular therapy.

[17]  R. Bammer,et al.  The MRA-DWI Mismatch Identifies Patients With Stroke Who Are Likely to Benefit From Reperfusion , 2008, Stroke.

[18]  Keith Muir,et al.  Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.

[19]  M. Moseley,et al.  Optimal Definition for PWI/DWI Mismatch in Acute Ischemic Stroke Patients , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Scott Hamilton,et al.  Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study , 2006, Annals of neurology.

[21]  Steven Warach,et al.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.

[22]  S. Warach,et al.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.

[23]  J. Alger,et al.  Beyond Mismatch: Evolving Paradigms in Imaging the Ischemic Penumbra With Multimodal Magnetic Resonance Imaging , 2003, Stroke.

[24]  G. Albers,et al.  Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. , 1999, Stroke.